President Donald Trump may want more pharmaceuticals made in America, but one of the world’s biggest generics companies says that’s not happening anytime soon. The CEO of generics drugmaker Sandoz, based in Switzerland, says new U.S. tariffs won’t be enough to bring manufacturing back onshore.